Key result
Review outlines CHD and ACS pathophysiology alongside initial management with thrombolysis, POBA, and bare-metal stents.
This review provides an overview of the pathophysiology of CHD and ACS, as well as historical and initial management strategies including thrombolysis, POBA, and bare metal stents.
Answers are grounded in this paper and cite their sources.
Offers foundational ACS overview for education; leaves open need for updated reviews on current therapies.
Coronary heart disease (CHD) continues to be a leading cause of morbidity and mortality in the western world. Pharmacological management with dual-antiplatelet therapy consisting of aspirin and a P2Y12 inhibitor forms the cornerstone of management of patients with CHD or an acute coronary syndrome (ACS). However, it is the use of interventional procedures, such as angioplasty and stenting to treat endothelial dysfunction secondary to atherosclerotic plaque rupture, that has revolutionised the management of patients who present with CHD including ACS. This is the first article in a two-part series, and provides an overview of the pathophysiology of CHD and ACS, as well as the initial strategies used in their management including thrombolysis, plain old balloon angioplasty (POBA) and bare metal stents.
No takes yet. Share an insight, caveat, or question.
Nazish Khan (2018) conducted a review in Coronary heart disease (CHD) and acute coronary syndrome (ACS). Coronary artery stents, POBA, and thrombolysis was evaluated. This review provides an overview of the pathophysiology of coronary heart disease and acute coronary syndrome, as well as initial management strategies including thrombolysis, POBA, and bare metal stents.
Synapse has enriched 10 related papers. Consider them for comparative context: